Survodutide
What it is
Survodutide, also identified by the development code BI 456906, is an investigational peptide that acts as a dual agonist at the glucagon receptor (GCGR) and the glucagon-like peptide-1 (GLP-1) receptor. It is a glucagon-derived sequence modified with a fatty diacid chain, a design associated with an extended half-life and once-weekly research schedules.
Research context and categorization
Survodutide falls under the metabolic and weight-regulation category of compounds, alongside other incretin-based dual and triple receptor agonists. It is a molecule engineered to engage two receptor pathways at once, and it is being developed by Boehringer Ingelheim in collaboration with Zealand Pharma.
In neutral research terms, survodutide is studied in the context of body-weight regulation, glycemic control, and liver-related metabolic endpoints. It is investigated for effects on energy balance, where GLP-1 receptor activity is commonly discussed in relation to appetite and gastric handling, and glucagon receptor activity is commonly discussed in relation to energy expenditure and hepatic fat metabolism. Much of the published clinical discussion centers on obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH, previously described as NASH) together with associated liver fibrosis.
Because survodutide is not FDA approved, all of these uses are investigational. They are the subject of ongoing trials and are not confirmed or approved benefits. Statements describing what it is studied for should not be read as established outcomes.
Status
- Regulatory status: Research-only and investigational. Survodutide is not FDA approved for any indication. It is in late-stage clinical development and has received FDA Breakthrough Therapy designation for non-cirrhotic MASH with fibrosis, which is a development pathway and not an approval.
- Sport status: Not specifically listed on the WADA Prohibited List. Survodutide is not named as a prohibited substance, and the broader GLP-1 receptor agonist class is currently on WADA's Monitoring Program rather than being prohibited. Monitoring status can change, so a current-year reference should be checked before relying on this.
Reconstitution notes (general)
Survodutide is typically supplied as a lyophilized (freeze-dried) powder that is reconstituted with bacteriostatic water before laboratory use. The working concentration follows a simple relationship: concentration equals the milligrams of peptide in the vial divided by the millilitres of bacteriostatic water added. For example, a 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL, while the same vial with 1 mL yields 5 mg/mL. A concentration calculator is available at /pages/tools.
Dilution and handling notes (compound-specific)
Survodutide is a reconstituted lyophilized peptide, so it does require mixing rather than arriving as a ready liquid. Common research references pair 5 mg and 10 mg vials with roughly 1 mL to 2 mL of bacteriostatic water, with the chosen water volume driven by the concentration a protocol targets rather than by a solubility limit.
Practical handling points reported for this peptide: - Allow the sealed vial to reach room temperature before opening, which reduces condensation inside the vial. - Add the water slowly against the inner glass wall rather than directly onto the powder cake, and swirl or roll gently. Do not shake, since agitation can foam and stress an acylated peptide like this one. - The powder generally dissolves readily and clears within about 30 to 60 seconds. A properly reconstituted solution should be clear and colorless. - Inspect before use. Cloudiness, discoloration, visible particulates, or floaters indicate the material should not be used.
Handling and storage
Store the reconstituted solution refrigerated at 2 to 8 C and keep it out of direct light. Wipe the stopper with an alcohol swab before each withdrawal, and label the vial with the date it was mixed. A refrigerated working solution is commonly referenced with an approximately 4-week (about 28-day) window. Avoid repeated freeze-thaw cycles, and discard the solution if it becomes cloudy or discolored or shows floaters.
Related reading
Tools and supplies
- Reconstitution & blend calculators
- Bacteriostatic Water 30 ml
- Gansulin Metal Reusable Pen
- 3 ml Glass Cartridges (10-pack)
- Complete Starter Kit
For laboratory and research reference only. Educational content, not medical, dosing, injection, or therapeutic guidance, and not intended for human or animal use. Any research uses described are investigational and not confirmed or approved benefits. Confirm anything involving health with a licensed professional. References linked above.